FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103414882> ?p ?o ?g. }

• W2103414882 endingPage "755" @default.
• W2103414882 startingPage "753" @default.
• W2103414882 abstract "Acute kidney injury (AKI) is a widespread problem in the intensive care unit (ICU) that heralds increased morbidity, mortality, and ICU length and cost of stay, independent of other factors (1–3). Unfortunately, there are few, if any, specific interventions proven to prevent or treat AKI. Renal replacement therapy is a reactionary, supportive therapy that almost by definition is started long after the inciting process and well into the pathophysiologic cascade of AKI. Although renal replacement therapy is effective at treating the sequelae of AKI such as electrolyte, fluid, and acid-base disorders, it does not address the underlying disease and is rather a bridge to hoped-for spontaneous renal recovery. Although many interventions have been studied to treat AKI and prevent its progression (4), nothing has been clearly beneficial, and we are left with the obvious yet nonspecific interventions: Maintain renal perfusion, avoid nephrotoxic drugs, and correct the underlying process (sepsis, hypovolemia). Many have suggested that at least one reason for the futility of interventions for AKI is late disease detection using conventional markers of renal function (4–7). That is, by the time azotemia and its sequelae are detected, renal injury is well established and may be outside the window for mitigation by an intervention (8). Part of the problem is that in contrast to many other acute disease states in which patients present with acute symptoms, patients with AKI are relatively asymptomatic until the disease is advanced. For example, in the case of acute myocardial infarction, patients typically present with symptoms of disease (chest pain, shortness of breath) that precipitate a workup including electrocardiogram and testing for relatively sensitive and early biomarkers such as troponin and CK-MB; however, what if acute myocardial infarction were a painless process? Myocardial ischemia would likely go undetected until perhaps several hours or even days after the initial event, when the patient presented with late signs and symptoms of the (now) irreversible infarction, such as new congestive heart failure or arrhythmia. In this scenario of late detection, it is easy to imagine that coronary angioplasty and stenting might be found to be ineffective therapies for myocardial injury. This problem of late detection of AKI is not new. In a classic example, multiple animal studies demonstrated that atrial natiuretic peptide was an effective treatment for AKI (9,10), yet atrial natiuretic peptide had no benefit in a well-performed large, randomized clinical trial (11). Despite the efforts of study investigators to identify patients early in the course of AKI, patients were enrolled relatively late, with a mean serum creatinine level of 4.5 mg/dl. Consequently, many investigators have explored the use of novel blood markers as sensitive and early biomarkers for AKI (12,13), arguing that the standard tests for AKI are late indicators with imperfect sensitivity and specificity, because they are altered under common clinical conditions such as trimethoprim and diuretic administration, sepsis, and fluid resuscitation. Although some of these new markers, including neutrophil gelatinase-associated lipocalin and kidney injury molecule 1 (14,15), are rapidly gaining approval by regulatory agencies for use in the clinical and preclinical settings, for the most part, these markers have not yet been broadly validated, are expensive, and are not widely available; however, there is increasing hope that these novel AKI biomarkers will soon be readily available in clinical practice. With the routine clinical use of novel biomarkers on the horizon, the question arises of how to use these biomarkers. Biomarkers, no matter how sensitive or well validated, will detect renal injury only when they are ordered as either widespread screening tests or, better yet, when renal injury is suspected. Widespread diagnostic testing may yield an unacceptable number of false-positive results. Thus, testing when renal injury is suspected may increase test specificity and be useful to trigger a therapy for AKI, because it is likely that such therapies need to be delivered early to be effective. The question becomes, “How can we suspect renal injury early enough to trigger biomarker testing and subsequent intervention aimed at the underlying pathophysiology of AKI?: Again, the acute coronary syndrome analogy seems useful: Because patients do not complain of an “anginal equivalent” with AKI, we are currently unable to identify patients who are at risk for early AKI and are candidates for further diagnostic testing. In this month's issue of CJASN, Goldstein and Chawla (16) address the dilemma of silent AKI by proposing a renal angina syndrome for critically ill adult and pediatric patients. Furthermore, they propose that AKI biomarkers used in conjunction with a renal angina syndrome will improve their performance as specific and sensitive indicators of AKI. The first step in the analogy to acute coronary syndrome is risk factor assessment. Just as there are well-established risk factors for coronary artery disease, the authors suggest that there are known risk factors for AKI that clinicians should consider as they risk-stratify patients for AKI, including age >65 years, diabetes, liver failure, congestive heart failure, chronic kidney disease, and cardiopulmonary bypass, among others. The authors suggest that in patients with risk factors for AKI, clinicians should be vigilant for “renal angina.” The authors propose that anginal equivalents include oliguria, small increases in serum creatinine, and volume overload. In the current environment, where novel biomarkers are not widely available, the presence of any of these anginal equivalents should trigger a more intensive investigation for early signs and symptoms of AKI, including urine microscopy and chemistries, as well as more frequent serum creatinine measurements and consideration of cystatin C measurements. In the future and where currently available, these patients would be excellent candidates for measurements of novel AKI biomarkers. A similar conceptual framework for AKI risk assessment and detection for pediatric patients uses slightly different risk factors and a slightly different definition for the syndrome itself and is based on the current pediatric literature. At present, AKI management remains the usual: Evaluation of treatable causes of AKI, optimizing renal perfusion, minimizing exposure to nephrotoxins, and management of fluid overload. However, the important hope is that identifying these patients on the basis of renal anginal equivalents and novel biomarkers will allow us to test novel therapies for AKI early in the course of the disease. Thus, what is novel about the conceptual framework proposed by Goldstein and Chawla is not the specific components of the approach, which if they are to be applied to current clinical practice are necessarily bound by the limitations of our current knowledge and capabilities, but rather the conceptual framework they present that will support the future of AKI assessment and treatment. Furthermore, the framework as proposed can now be tested by investigators to determine, for example, whether there are specific cutoffs that are useful for the proposed anginal equivalents, as well as to understand the risk for developing severe AKI (say, a doubling of serum creatinine) on the basis of a patient's constellation of risk factors and renal angina symptoms. Along the same lines, a goal of future biomarker studies may be to develop cut points that are useful in a population with renal angina—for example, a cut point above which patients with renal angina are extremely likely to develop severe AKI. This might in turn allow targeted delivery of novel therapies to those individuals with the goal of preventing or mitigating severe AKI. As our knowledge of AKI evolves, so will the definitions, criteria, and tools that compose this approach. Nonetheless, the underlying structure of a systematic risk assessment, early investigation, and prompt therapy provides a useful and testable framework for future study and clinical management of AKI that will allow the field to move forward. Disclosures None." @default.
• W2103414882 created "2016-06-24" @default.
• W2103414882 creator A5066441344 @default.
• W2103414882 creator A5069217164 @default.
• W2103414882 date "2010-05-01" @default.
• W2103414882 modified "2023-10-17" @default.
• W2103414882 title "Acute Renal Syndrome/Renal Angina" @default.
• W2103414882 cites W1531106656 @default.
• W2103414882 cites W1968425658 @default.
• W2103414882 cites W1986347387 @default.
• W2103414882 cites W2010668846 @default.
• W2103414882 cites W2012029042 @default.
• W2103414882 cites W2044621438 @default.
• W2103414882 cites W2114561453 @default.
• W2103414882 cites W2117958746 @default.
• W2103414882 cites W2139153272 @default.
• W2103414882 cites W2143262001 @default.
• W2103414882 cites W2146942628 @default.
• W2103414882 cites W2321262365 @default.
• W2103414882 cites W4231980339 @default.
• W2103414882 cites W4234830388 @default.
• W2103414882 doi "https://doi.org/10.2215/cjn.02360310" @default.
• W2103414882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20378643" @default.
• W2103414882 hasPublicationYear "2010" @default.
• W2103414882 type Work @default.
• W2103414882 sameAs 2103414882 @default.
• W2103414882 citedByCount "4" @default.
• W2103414882 countsByYear W21034148822015 @default.
• W2103414882 countsByYear W21034148822017 @default.
• W2103414882 countsByYear W21034148822021 @default.
• W2103414882 crossrefType "journal-article" @default.
• W2103414882 hasAuthorship W2103414882A5066441344 @default.
• W2103414882 hasAuthorship W2103414882A5069217164 @default.
• W2103414882 hasBestOaLocation W21034148821 @default.
• W2103414882 hasConcept C126322002 @default.
• W2103414882 hasConcept C159641895 @default.
• W2103414882 hasConcept C164705383 @default.
• W2103414882 hasConcept C2777698277 @default.
• W2103414882 hasConcept C500558357 @default.
• W2103414882 hasConcept C71924100 @default.
• W2103414882 hasConceptScore W2103414882C126322002 @default.
• W2103414882 hasConceptScore W2103414882C159641895 @default.
• W2103414882 hasConceptScore W2103414882C164705383 @default.
• W2103414882 hasConceptScore W2103414882C2777698277 @default.
• W2103414882 hasConceptScore W2103414882C500558357 @default.
• W2103414882 hasConceptScore W2103414882C71924100 @default.
• W2103414882 hasIssue "5" @default.
• W2103414882 hasLocation W21034148821 @default.
• W2103414882 hasLocation W21034148822 @default.
• W2103414882 hasOpenAccess W2103414882 @default.
• W2103414882 hasPrimaryLocation W21034148821 @default.
• W2103414882 hasRelatedWork W2031269965 @default.
• W2103414882 hasRelatedWork W2133964071 @default.
• W2103414882 hasRelatedWork W2187342990 @default.
• W2103414882 hasRelatedWork W2525778866 @default.
• W2103414882 hasRelatedWork W2560790490 @default.
• W2103414882 hasRelatedWork W2596660188 @default.
• W2103414882 hasRelatedWork W2737074397 @default.
• W2103414882 hasRelatedWork W2760815731 @default.
• W2103414882 hasRelatedWork W2761476198 @default.
• W2103414882 hasRelatedWork W3013716928 @default.
• W2103414882 hasVolume "5" @default.
• W2103414882 isParatext "false" @default.
• W2103414882 isRetracted "false" @default.
• W2103414882 magId "2103414882" @default.
• W2103414882 workType "article" @default.